Cancer
... MYC Inactivation Uncovers Pluripotent Differentiation and Tumor Dormancy in Hepatocellular Cancer Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandi S, Bachman MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, ...
... MYC Inactivation Uncovers Pluripotent Differentiation and Tumor Dormancy in Hepatocellular Cancer Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandi S, Bachman MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, ...
Gene Section TFAP2C (transcription factor AP-2 gamma Atlas of Genetics and Cytogenetics
... overall and 76% identity in C-terminal part. The consensus site from the ChIP-seq data, SCCTSRGGS (S=G/C, r=A/G), is consistent with the optimal binding site, GCCTGAGGG, which was determined by in vitro PCR-assisted binding site selection (Woodfield et al., 2010). Estrogen receptor-alpha (ESR1) and ...
... overall and 76% identity in C-terminal part. The consensus site from the ChIP-seq data, SCCTSRGGS (S=G/C, r=A/G), is consistent with the optimal binding site, GCCTGAGGG, which was determined by in vitro PCR-assisted binding site selection (Woodfield et al., 2010). Estrogen receptor-alpha (ESR1) and ...
Tuesday November, 14 Poster Session 3
... Smad4 is a central mediator of the TGF-beta-related signaling and is implicated in numerous biological and disease processes including control of cellular growth, differentiation, migration, and extracellular matrix production; these processes are all essential for normal development. Targeted disru ...
... Smad4 is a central mediator of the TGF-beta-related signaling and is implicated in numerous biological and disease processes including control of cellular growth, differentiation, migration, and extracellular matrix production; these processes are all essential for normal development. Targeted disru ...
Tmm - OpenWetWare
... Chip_Platform GPL96: Affymetrix GeneChip Human Genome U133 Array Set HG-U133A for 712X712 ...
... Chip_Platform GPL96: Affymetrix GeneChip Human Genome U133 Array Set HG-U133A for 712X712 ...
Reproductive cloning
... • field that compares the entire DNA content of different organisms – the genome: the full complement of genetic information of an organism (i.e., all of its genes and other DNA) – DNA sequencing: a process that allows scientists to read each nucleotide in a strand of DNA ...
... • field that compares the entire DNA content of different organisms – the genome: the full complement of genetic information of an organism (i.e., all of its genes and other DNA) – DNA sequencing: a process that allows scientists to read each nucleotide in a strand of DNA ...
microarray_ALL_vs_AM..
... Above you saw the use of the microarray to diagnose ALL vs AML. We could already do this prior to the advent of microarrays. So what new information and abilities does the microarray allow? • Diagnosis - We now know all the genes that are differentially expressed between the two types of leukemia al ...
... Above you saw the use of the microarray to diagnose ALL vs AML. We could already do this prior to the advent of microarrays. So what new information and abilities does the microarray allow? • Diagnosis - We now know all the genes that are differentially expressed between the two types of leukemia al ...
Class Presentation Questions 12
... _________________________=mutations that produce changes in a single gene. _________________________=mutations that produce changes in whole chromosomes. A mutation that involves a single nucleotide is called a(an)__________________________. What is a substitution(gene mutation)? How many nucleotide ...
... _________________________=mutations that produce changes in a single gene. _________________________=mutations that produce changes in whole chromosomes. A mutation that involves a single nucleotide is called a(an)__________________________. What is a substitution(gene mutation)? How many nucleotide ...
Questions
... 3) Describe the 3 ways genetic recombination can occur in bacteria. (CUES: transformation, Griffith, transduction, phage, mating bridge, conjugation) 4) In a rapidly changing environment, which bacterial population would likely be more successful, one that includes individuals capable of conjugation ...
... 3) Describe the 3 ways genetic recombination can occur in bacteria. (CUES: transformation, Griffith, transduction, phage, mating bridge, conjugation) 4) In a rapidly changing environment, which bacterial population would likely be more successful, one that includes individuals capable of conjugation ...
Two Epigenetic Mechanisms
... Refers to changes in gene expression caused by mechanisms other than changes in the underlying DNA sequence. Enables a cell/organism to respond to its dynamic external environment during development and throughout life! Epigenetic changes to the genome can be inherited if these changes occur in cell ...
... Refers to changes in gene expression caused by mechanisms other than changes in the underlying DNA sequence. Enables a cell/organism to respond to its dynamic external environment during development and throughout life! Epigenetic changes to the genome can be inherited if these changes occur in cell ...
Chapter 5 Mutation and genetic variation
... tracked 74 family lines derived from one female and followed each for 214 generations. At end sequenced 771,672 base pairs of mitochondrial DNA. Found 26 mutations giving rate of 1.6X10-7 mutations per site per generation. Ten mutations were insertion/deletions and 16 substitutions. ...
... tracked 74 family lines derived from one female and followed each for 214 generations. At end sequenced 771,672 base pairs of mitochondrial DNA. Found 26 mutations giving rate of 1.6X10-7 mutations per site per generation. Ten mutations were insertion/deletions and 16 substitutions. ...
PPT Version - OMICS International
... • Historically –suspected based on several lines of evidence: • Malignant phenotype suppressed by fusion with normal cells (presence of tumour suppressor in normal implied). • Chromosomal losses in hybrids caused reversion to malignant phenotype. • Introduction of single chromosomes into malignant ...
... • Historically –suspected based on several lines of evidence: • Malignant phenotype suppressed by fusion with normal cells (presence of tumour suppressor in normal implied). • Chromosomal losses in hybrids caused reversion to malignant phenotype. • Introduction of single chromosomes into malignant ...
Questions - Vanier College
... the relationship between the genome and the proteome, what is the most likely relationship between your proteome and that of your classmate? A. More than 99.9 percent identical B. 99.9 percent identical C. Less than 99.9 percent identical ...
... the relationship between the genome and the proteome, what is the most likely relationship between your proteome and that of your classmate? A. More than 99.9 percent identical B. 99.9 percent identical C. Less than 99.9 percent identical ...
Mutations 1
... In transition mutation, pyrimidine base is changed to another pyrimidine or purine base is changed to another purine base In transversions mutations, purine base is changed into either of two pyrimidines and vice versa. ...
... In transition mutation, pyrimidine base is changed to another pyrimidine or purine base is changed to another purine base In transversions mutations, purine base is changed into either of two pyrimidines and vice versa. ...
Sex determination
... – F white X M green > – F white X M variegated > – F green X M white > – F green X M variegated > – F variegated X M green > – F variegated X M white > ...
... – F white X M green > – F white X M variegated > – F green X M white > – F green X M variegated > – F variegated X M green > – F variegated X M white > ...
CH21
... Many cancers involve the inactivation of genes whose products play important roles in regulating the cell cycle. C-ras and c-myc……genes required for regulation cell cycle. -increase activity and/or concentration-----oncogene----may form tumors. ...
... Many cancers involve the inactivation of genes whose products play important roles in regulating the cell cycle. C-ras and c-myc……genes required for regulation cell cycle. -increase activity and/or concentration-----oncogene----may form tumors. ...
Gene expression
... G1 –gap, decide whether to proliferate, wait or cross to non-dividing stage G0 S -- DNA Synthesis G2– gap, allow DNA repair ...
... G1 –gap, decide whether to proliferate, wait or cross to non-dividing stage G0 S -- DNA Synthesis G2– gap, allow DNA repair ...
An alternative model for (breast) cancer predisposition
... gene is involved in the maintenance of DNA integrity, and a recurrent protein truncating mutation (c.1100delC) is responsible for increased cancer risk in a fraction of BC families. However, the uncomplicated co-segregation pattern seen in BRCA1 and BRCA2 families, where (almost) all BC patients car ...
... gene is involved in the maintenance of DNA integrity, and a recurrent protein truncating mutation (c.1100delC) is responsible for increased cancer risk in a fraction of BC families. However, the uncomplicated co-segregation pattern seen in BRCA1 and BRCA2 families, where (almost) all BC patients car ...
Oncogenomics
Oncogenomics is a relatively new sub-field of genomics that applies high throughput technologies to characterize genes associated with cancer. Oncogenomics is synonymous with ""cancer genomics"". Cancer is a genetic disease caused by accumulation of mutations to DNA leading to unrestrained cell proliferation and neoplasm formation. The goal of oncogenomics is to identify new oncogenes or tumor suppressor genes that may provide new insights into cancer diagnosis, predicting clinical outcome of cancers, and new targets for cancer therapies. The success of targeted cancer therapies such as Gleevec, Herceptin, and Avastin raised the hope for oncogenomics to elucidate new targets for cancer treatment.Besides understanding the underlying genetic mechanisms that initiates or drives cancer progression, one of the main goals of oncogenomics is to allow for the development of personalized cancer treatment. Cancer develops due to an accumulation of mutations in DNA. These mutations accumulate randomly, and thus, different DNA mutations and mutation combinations exist between different individuals with the same type of cancer. Thus, identifying and targeting specific mutations which have occurred in an individual patient may lead to increased efficacy of cancer therapy.The completion of the Human Genome Project has greatly facilitated the field of oncogenomics and has increased the abilities of researchers to find cancer causing genes. In addition, the sequencing technologies now available for sequence generation and data analysis have been applied to the study of oncogenomics. With the amount of research conducted on cancer genomes and the accumulation of databases documenting the mutational changes, it has been predicted that the most important cancer-causing mutations, rearrangements, and altered expression levels will be cataloged and well characterized within the next decade.Cancer research may look either on the genomic level at DNA mutations, the epigenetic level at methylation or histone modification changes, the transcription level at altered levels of gene expression, or the protein level at altered levels of protein abundance and function in cancer cells. Oncogenomics focuses on the genomic, epigenomic, and transcript level alterations in cancer.